journal article·2008-08-26

Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform

Liangfang Zhang, Juliana M. Chan, Frank X. Gu, June-Wha Rhee, Andrew Z. Wang, Aleksandar F. Radovic-Moreno, Frank Alexis, Robert Langer, Omid C. Farokhzad

ACS Nano· Volume 2· Issue 8
Publisher page

Abstract

We report the engineering of a novel lipid-polymer hybrid nanoparticle (NP) as a robust drug delivery platform, with high drug encapsulation yield, tunable and sustained drug release profile, excellent serum stability, and potential for differential targeting of cells or tissues. The NP comprises three distinct functional components: (i) a hydrophobic polymeric core where poorly water-soluble drugs can be encapsulated; (ii) a hydrophilic polymeric shell with antibiofouling properties to enhance NP stability and systemic circulation half-life; and (iii) a lipid monolayer at the interface of the core and the shell that acts as a molecular fence to promote drug retention inside the polymeric core, thereby enhancing drug encapsulation efficiency, increasing drug loading yield, and controlling drug release. The NP is prepared by self-assembly through a single-step nanoprecipitation method in a reproducible and predictable manner, making it potentially suitable for scale-up.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipid Membrane Structure and Behavior · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering and Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

References (20)

Show source-provided references
1. Ferrari M. · Nat. Rev. Cancer · 2005 · 5 · 16110.1038/nrc1566 ↗
2. Langer R. · Nature · 1998 · 392 · 5
3. Jiang W. · Nat. Nanotechnol. · 2008 · 3 · 14510.1038/nnano.2008.30 ↗
4. Farokhzad O. C. · Adv. Drug Delivery Rev. · 2006 · 58 · 145610.1016/j.addr.2006.09.011 ↗
5. Zhang L. · Clin. Pharmacol. Ther. · 2008 · 83 · 76110.1038/sj.clpt.6100400 ↗
6. Wagner V. · Nat. Biotechnol. · 2006 · 24 · 121110.1038/nbt1006-1211 ↗
7. Farokhzad O. C. · Proc. Natl. Acad. Sci. U.S.A. · 2006 · 103 · 631510.1073/pnas.0601755103 ↗
8. Torchilin V. P. · Pharm. Res. · 2007 · 24 · 110.1007/s11095-006-9132-0 ↗
9. Tong R. · Polym. Rev. · 2007 · 47 · 34510.1080/15583720701455079 ↗
10. Kim T. Y. · Clin. Cancer Res. · 2004 · 10 · 370810.1158/1078-0432.CCR-03-0655 ↗
11. Moghimi S. M. · Prog. Lipid Res. · 2003 · 42 · 46310.1016/S0163-7827(03)00033-X ↗
12. Torchilin V. P. · Nat. Rev. Drug Discovery · 2005 · 4 · 14510.1038/nrd1632 ↗
13. Skubitz K. M. · Cancer Invest. · 2003 · 21 · 16710.1081/CNV-120016412 ↗
14. De Miguel I. · Pharm. Res. · 2000 · 17 · 81710.1023/A:1007504124603 ↗
15. Wong H. L. · J. Controlled Release · 2006 · 116 · 27510.1016/j.jconrel.2006.09.007 ↗
16. Thevenot J. · Biomacromolecules · 2007 · 8 · 365110.1021/bm700753q ↗
17. Moghimi S. M. · Pharmacol. Rev. · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
18. Gu F. · Proc. Natl. Acad. Sci. U.S.A. · 2008 · 105 · 258610.1073/pnas.0711714105 ↗
19. Lupold S. E. · Cancer Res. · 2002 · 62 · 4029
20. Zhang L. · ChemMedChem · 2007 · 2 · 126810.1002/cmdc.200700121 ↗